Compare Globus Medical Inc. Class A Common Stock (GMED) vs ProShares Ultra Gold ETF (UGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs ProShares Ultra Gold ETF — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.99 (market cap $10.25B), while ProShares Ultra Gold ETF trades at $45.28 (market cap $730.54M). The key difference: Globus Medical Inc. Class A Common Stock is far larger — about 14× ProShares Ultra Gold ETF's market cap, and Globus Medical Inc. Class A Common Stock is trading nearer its 52-week high, ProShares Ultra Gold ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and ProShares Ultra Gold ETF for 25 Days on average.
| GMED | UGL | |
|---|---|---|
Market Cap | $10.25B | $730.54M |
Volume | 1,059,528 | 4,212,910 |
Sector | Health | Leveraged / Inverse |
52-Week High | $96.82 | $85.62 |
52-Week Low | $58.33 | $42.79 |
Typical Hold Time | 0 Days | 25 Days |
Enterprise Value | $9.76B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
UGL stock trades at $45.70, down 0.39% with bearish technical signals from moving averages. The stock faces pressure from broader market headwinds including rising Treasury yields and Federal Reserve policy uncertainty. Recent news highlights gold's struggle to maintain momentum despite intermittent safe-haven demand, with prices testing key support levels amid mixed economic data.
The outlook remains cautious with technical indicators suggesting continued near-term pressure. Investment opportunity exists for contrarian investors if gold regains its safe-haven appeal, though risks include persistent rate hike expectations and dollar strength. The stock's performance remains tightly linked to gold price movements and macroeconomic developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About ProShares Ultra Gold ETF
UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.
Read more on UGL →
